{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:57Z","timestamp":1790821557805,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.msard.2022.104491","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T21:20:04Z","timestamp":1672176004000},"page":"104491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2818-3780","authenticated-orcid":false,"given":"Per Soelberg","family":"Sorensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Pontieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Joensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Heick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Vestergaard","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Ratzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Ellinore","family":"Pihl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104491_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcv.2016.12.005","article-title":"Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine","volume":"88","author":"Alstadhaug","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.msard.2022.104491_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108571","article-title":"2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells","volume":"105","author":"Aybar","year":"2022","journal-title":"Int. Immunopharmacol"},{"issue":"4","key":"10.1016\/j.msard.2022.104491_bib0003","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2022.104491_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102769","article-title":"Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis","volume":"49","author":"Bartosik-Psujek","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"8825","key":"10.1016\/j.msard.2022.104491_bib0005","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2022.104491_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102945","article-title":"A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis","volume":"52","author":"Bose","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.msard.2022.104491_bib0007","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1345\/aph.1H037","article-title":"Cladribine: an investigational immunomodulatory agent for multiple sclerosis","volume":"40","author":"Brousil","year":"2006","journal-title":"Ann.Pharmacother"},{"issue":"5","key":"10.1016\/j.msard.2022.104491_bib0008","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook","year":"2011","journal-title":"Mult.Scler"},{"issue":"4","key":"10.1016\/j.msard.2022.104491_bib0009","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001187","article-title":"Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS","volume":"9","author":"de Stefano","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2022.104491_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103490","article-title":"Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years","volume":"58","author":"Disanto","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2022.104491_bib0011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1074\/jbc.275.1.29","article-title":"Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway","volume":"275","author":"Genini","year":"2000","journal-title":"J Biol.Chem"},{"issue":"5","key":"10.1016\/j.msard.2022.104491_bib0012","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N.Engl.J.Med"},{"key":"10.1016\/j.msard.2022.104491_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.msard.2022.104491_bib0014","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2022.104491_bib0015","article-title":"Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study","author":"Giovannoni","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2022.104491_bib0016","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","author":"Giovannoni","year":"2017","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.msard.2022.104491_bib0017","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.msard.2022.104491_bib0018","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1177\/1352458517728812","article-title":"Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis","volume":"24","author":"Kalincik","year":"2018","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.msard.2022.104491_bib0019","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/135245850000600306","article-title":"The Danish National Project of interferon-beta treatment in relapsing- remitting multiple sclerosis. The Danish Multiple Sclerosis Group","volume":"6","author":"Koch-Henriksen","year":"2000","journal-title":"Mult.Scler"},{"issue":"1","key":"10.1016\/j.msard.2022.104491_bib0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.msard.2022.104491_bib0021","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.msard.2022.104491_bib0022","doi-asserted-by":"crossref","first-page":"e01921","DOI":"10.1002\/brb3.1921","article-title":"The Danish Multiple Sclerosis Registry","volume":"11","author":"Magyari","year":"2021","journal-title":"Brain Behav"},{"key":"10.1016\/j.msard.2022.104491_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103812","article-title":"Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis","volume":"62","author":"Nygaard","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2022.104491_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/nmt-2021-0041","article-title":"Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary","volume":"12","author":"Oh","year":"2022","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.msard.2022.104491_bib0025","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","author":"Pfeuffer","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2022.104491_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103755","article-title":"Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study","volume":"61","author":"Rauma","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2022.104491_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836913","article-title":"Pulsed immune reconstitution therapy in multiple sclerosis","volume":"12","author":"Sorensen","year":"2019","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822009956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:49Z","timestamp":1761901429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822009956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":27,"alternative-id":["S2211034822009956"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104491","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104491"}}